LO3A Stock Overview
Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Lonza Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 58.50 |
| 52 Week High | CHF 61.50 |
| 52 Week Low | CHF 36.40 |
| Beta | 0.64 |
| 1 Month Change | 5.41% |
| 3 Month Change | 2.63% |
| 1 Year Change | 61.60% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| LO3A | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 3.5% | -2.8% | -2.0% |
| 1Y | 61.6% | -5.6% | 6.8% |
Return vs Industry: LO3A exceeded the German Life Sciences industry which returned -5.9% over the past year.
Return vs Market: LO3A exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| LO3A volatility | |
|---|---|
| LO3A Average Weekly Movement | 5.3% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LO3A has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: LO3A's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 17,834 | Wolfgang Wienand | www.lonza.com |
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.
Lonza Group AG Fundamentals Summary
| LO3A fundamental statistics | |
|---|---|
| Market cap | €41.12b |
| Earnings (TTM) | €612.69m |
| Revenue (TTM) | €7.16b |
67.1x
P/E Ratio5.7x
P/S RatioIs LO3A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LO3A income statement (TTM) | |
|---|---|
| Revenue | CHF 6.70b |
| Cost of Revenue | CHF 4.29b |
| Gross Profit | CHF 2.41b |
| Other Expenses | CHF 1.84b |
| Earnings | CHF 573.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Jan 29, 2025
| Earnings per share (EPS) | 7.93 |
| Gross Margin | 36.01% |
| Net Profit Margin | 8.56% |
| Debt/Equity Ratio | 40.3% |
How did LO3A perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield50%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 13:51 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lonza Group AG is covered by 50 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martin Schnee | AlphaValue |
| Volker Bosse | Baader Helvea Equity Research |
| Charles Pitman-King | Barclays |